TRUP · Trupanion, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on TRUP. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About TRUP · Trupanion, Inc.
Trupanion, Inc., together with its subsidiaries, provides medical insurance for cats and dogs on subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians. The company was formerly known as Vetinsurance International, Inc. changed its name to Trupanion, Inc. in 2013. The company was founded in 2000 and is headquartered in Seattle, Washington.
Live Quote
SELL (score -5) · 12-1 mom -61.3% · RSI 53.1 · below_both · -58.2% from high
Targets blend Wall Street consensus (4 analysts: low $28.00 / mean $39.75 / high $52.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Anti-signals (going-concern, dilution, concentration) are present and unaddressed, combined with zero insider buying, deteriorating quality metrics, and a technically broken chart. The erratic earnings history confirms this is a value trap, not a mispricing opportunity, and no income structure offers a clear edge over the downside risk.
Anti-signals (going-concern, dilution, concentration) are present and unaddressed, combined with zero insider buying, deteriorating quality metrics, and a technically broken chart. The erratic earnings history confirms this is a value trap, not a mispricing opportunity, and no income structure offers a clear edge over the downside risk.
Despite 25 Form-4 filings in the past 14 days triggering the investigation, every single transaction was RSU vesting (code M) with tax withholdings (code F). No open-market purchases (P-code) were found. The stock is deeply oversold — down ~62% from its 52-week high of $57.89, RSI at 32.3, below both the 50DMA and 200DMA — but this bearish technical picture is real and consistent with the price decline. Q1 2026 results showed a return to profitability (EPS $0.11 vs -$0.03 year-ago) on +12% revenue growth, yet shares have continued declining. The forward P/E of ~5x looks inexpensive relative to sector peers but reflects genuine uncertainty about whether this pet-insurance leader can sustain margin expansion amid rising veterinary costs. No material filing edge was uncovered; the narrative is straightforward and the market appears aware of it.